2,646 press releases indexed under automotive.
Special Purpose Vehicle to Be Formed in Connection With Proposed Transaction
(PR-inside.com) AI-powered career transition platform recognized for combining labor market insights, human coaching, and job search tools in one system. Users in LHH's Career Transition program find new roles 32 days faster with the platform. NEW YORK CITY, NY / ACCESS Newswire / August 13, 2026 /Overview LHH Career Transition & Mobility, the leading talent transformation solutions business within the Adecco Group, today announced that LHH Career Studio has won the Career Development Innovation Award in the inaugural 2026 HR Tech Breakthrough Awards program. LHH was selected from hundreds of nominations spanning the global HR technology landscape, in a winners' group that includes ..
(PR-inside.com) ESTERO, FL / ACCESS Newswire / August 13, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced that management will be present and host one-on-one meetings with investors at Sidoti & Company's Micro-Cap Virtual Investor Conference taking place on August 19-20, 2026. Management plans to discuss its clinical and commercial development pipeline and its recently closed acquisition of Dura Driver Control Systems, a leading global automotive supplier with a 100+ year history and $200M+ in 2025 revenue. Sidoti Micro-Cap Virtual Conference Presentation DetailsDates: August 19-20, 2026 Date and Time: Wednesday, August 19, 2026, at 1:45 P.M. ET Webcast: ..
(PR-inside.com) The new order is a rear-view mirror program combining Driver Monitoring System (DMS) and Occupant Monitoring System (OMS) software for three vehicles, with possibilities for further vehicle program extensions. Based on projected product life cycle volumes, the estimated revenue is SEK 100 million. GÖTEBORG, SE / ACCESS Newswire / August 13, 2026 / Smart Eye (STO:SEYE)(OTC PINK:SMTEF)(FRA:SE9) - Smart Eye, a global leader in DMS and OMS for the automotive industry, has been selected to deliver its technology to three new car models from a major European OEM with a global footprint, which has previously sourced Smart Eye's OMS software using ..
(PR-inside.com) FREMONT, CA / ACCESS Newswire / August 13, 2026 / Aehr Test Systems (NASDAQ:AEHR), a leading provider of test and burn-in solutions for semiconductor devices used in artificial intelligence (AI), silicon photonics, data center, automotive, and industrial applications, today announced that it will participate in the 7th Annual Needham Virtual Semiconductor and SemiCap 1x1 Conference on Wednesday, August 19, 2026. Aehr Test President and CEO Gayn Erickson and CFO Chris Siu will be hosting virtual meetings with investors throughout the day. "We look forward to discussing with investors and shareholders Aehr's expanding role in enabling the next generation of semiconductor devices ..
FAIRPORT, N.Y, August 13, 2026--Monro, Inc. (Nasdaq: MNRO), a leading provider of automotive repair and tire services, today announced that its Board of Directors has declared a quarterly cash dividend of $.28 per share on the Company’s outstanding shares of common stock. The dividend is payable on September 8, 2026, to shareholders at the close of business on August 25, 2026.
AMSTERDAM/HONG KONG, August 13, 2026 - (ACN Newswire) - Kefi B.V., a major shareholder and principal creditor of WSC Group (the owner and promoter of the globally recognized TCR Series), together with its aligned shareholders, today announced a comprehensive strategic vision aimed at accelerating the commercial growth of the TCR platform and bringing WSC WORLD SPORTING CONSULTING LIMITED (WSC Group) to a public listing on a major international exchange in the near future. The Foundation: Kefi's Decisive Role in Building the TCR Ecosystem Kefi B.V. and its predecessor entity have invested the largest amount of capital into WSC Group among all shareholders since 2018, while simultaneously providing strategic resources and support to fellow shareholders throughout this period. This commitment was made well before the Fédération Internationale de l'Automobile (FIA) adopted the TCR Regulations as its global touring car standard. Kefi's high-conviction capital investment proved decisive, enabling the seamless integration of FIA standards and the global debut of the first commercially available road car bearing the TCR brand. Following this foundational investment, WSC Group successfully launched landmark co-branding initiatives with major automotive manufacturers. In 2019, the Volkswagen Golf GTI TCR road car was introduced to the European and Asian markets, pushing sales significantly with the strength of the TCR brand and becoming a sought-after performance icon. In 2021, the Hyundai Elantra N TCR Edition further demonstrated the power of the TCR brand to drive consumer car sales in global markets. These achievements confirm that the commercial potential of the TCR ecosystem is limitless, extending far beyond the racetrack and into the showrooms of the world's largest automakers. Beyond Capital: Kefi's Strategic Partnership and Long-Term Support Kefi B.V.'s contribution to WSC Group has extended far beyond capital injections. Over nearly a decade of close collaboration, Kefi has provided continuous long-term strategic support: referring high-value business networks and introducing real commercial opportunities to the company and its shareholders, offering professional advisory services on corporate governance, legal structuring, and financial strategy, and connecting WSC Group with strategic partners across the automotive, technology, and media sectors. "Over nearly ten years of close collaboration, we have grown alongside WSC," stated a spokesperson for Kefi B.V. "We have deep insight into the company's inner circle, its daily workings, and its operational details. We maintain absolute clarity regarding our rights as a major shareholder and creditor, and we believe the time has come to unlock the true, unmaximised value of this extraordinary global IP." Kefi as the Institutional Interface for WSC Given its extensive expertise in global laws, regulations, and capital markets, Kefi B.V. acts as the primary communication channel on behalf of WSC Group when engaging with institutional investors and sophisticated partners. This role ensures that WSC Group's engagement with the global investment community meets the highest standards of professionalism, regulatory compliance, and fiduciary transparency, standards that are essential for the company's path to a public listing. Kefi's efforts in this capacity have already brought tangible benefits to all minority shareholders by enhancing the company's credibility, expanding its investor base, and laying the groundwork for a liquidity event that will deliver significant value to all stakeholders. A New Chapter: Evolving for the Next Phase of Growth The TCR ecosystem has now matured into a global institution operating across more than 40 countries with over 16 major manufacturers. The scale and complexity of the business today demands institutional governance, centralized commercial expertise, and capital markets experience to take the platform to its next level of growth. Kefi B.V. and its aligned shareholders are therefore advocating for the introduction of enhanced professional structures and a business model upgrade that matches the ambition and scale of the opportunity ahead. From Grassroots to World-Class: A Platform for All Drivers At its core, TCR cars remain the most affordable and exciting category in global motorsport. With a complete race-ready car costing a fraction of GT3 or single-seater alternatives, TCR delivers thrilling, close-contact touring car racing that is accessible to a wide range of participants. Yet affordability does not come at the expense of competition quality. The TCR Series attracts the full spectrum of driving talent, from passionate gentleman drivers to top-tier professionals with elite driving skills competing at the highest level of touring car racing. This unique combination of accessibility and world-class competition is what sets the TCR Series apart and gives WSC an unrivalled depth of driver engagement across all levels. Kefi B.V. and its aligned shareholders aim to bring the enthusiasm of motorsport back to the world, to reignite the passion that comes from watching production-based cars, driven by relatable heroes, battling bumper-to-bumper on circuits and street tracks across every continent. Unprecedented Growth and Media Value The TCR ecosystem has demonstrated explosive growth. According to recent data certified by IRIS Sport, the Kumho FIA TCR World Tour saw its total media value increase by 103% in the past season alone. Global reach expanded by 33% to 296 million, generating 1.58 billion media contacts. With over 900 hours of broadcasting and a rapidly expanding digital footprint, the TCR ecosystem has proven its capability to deliver massive international visibility, particularly in high-growth markets such as China, Pan-Asia, and Latin America. The TCR Ecosystem: Beyond Traditional Racing The TCR ecosystem extends well beyond traditional circuit racing. WSC Group's intellectual property encompasses a comprehensive portfolio of assets and growth verticals, including e-sports and competitive sim racing, video gaming (PC and mobile applications), legal street racing events that bring motorsport directly to city centres, the ETCR (Electric) and HTCR (Hybrid) platforms for next-generation powertrains, and TCR-branded racing academies and driving experiences. This breadth of the ecosystem positions WSC Group as a multi-dimensional sports, entertainment, and technology platform with numerous avenues for monetisation and audience growth. Fundraising and Use of Proceeds To capitalize on this momentum, Kefi B.V. and its aligned shareholders are actively pursuing a new round of fundraising to prepare WSC Group for a public listing. The proceeds will be deployed towards: - General Working Capital: Strengthening the operational foundation and supporting day-to-day business expansion across all markets. - Research & Development and TCR Lab: Establishing a dedicated TCR Lab focused on advancing new materials for car kits and components, developing the ETCR (Electric) and HTCR (Hybrid) platforms, and integrating cutting-edge technologies such as solid-state batteries. The TCR Lab will position the ecosystem as the ultimate R&D testing ground for the automotive industry, attracting manufacturer investment and accelerating innovation. - Marketing and Fan Engagement: Expanding global broadcasting partnerships, developing digital content strategies, building experiential fan engagement platforms, and deepening relationships with drivers, racing teams, and national promoters worldwide. Future Growth Through Strategic Acquisitions Looking ahead, Kefi B.V. will leverage its extensive global networks and M&A expertise to identify and execute strategic acquisitions that complement and expand the TCR ecosystem. This may include acquiring complementary motorsport properties, technology platforms, media assets, or regional promotion rights that accelerate WSC Group's path to becoming the dominant global touring car and accessible motorsport conglomerate. Valuation Outlook: Exponential Upside Based on peer comparisons with publicly listed motorsport properties, including Formula 1 (market capitalization exceeding US$22 billion) and MotoGP (acquired by Liberty Media for €4.2 billion at 8.8x revenue), the future valuation of WSC Group upon achieving a public listing is expected to be exponentially higher than its current private valuation. The TCR ecosystem's unmatched global footprint (40+ series, 200+ annual races, 1,000+ cars, 16+ manufacturers) and its rare FIA endorsement represent an IP asset with no direct comparable at its current valuation level. Early investors stand to benefit from a significant valuation re-rating as the company transitions from a privately held entity to a publicly listed global sports and entertainment platform. Welcoming New Partnerships Kefi B.V. and its aligned shareholders warmly welcome new partnerships with major car manufacturers, leading technology companies, and upstream/downstream supply chain participants who share the vision of building the TCR ecosystem into the world's premier accessible motorsport platform. About WSC Group and the TCR Ecosystem Founded in 2014, WSC Group is the sole owner of the TCR (Touring Car Racing) technical regulations. TCR is the most successful customer racing concept of the 21st century, currently licensed to over 40 national and regional series globally, encompassing more than 200 annual races. Over 1,000 TCR-specification cars have been built by more than 16 major automotive manufacturers, including Alfa Romeo, Audi, Cupra, Geely, Honda, Hyundai, Peugeot, Toyota, and Volkswagen. In a rare endorsement, the FIA adopted the private TCR regulations for its top-tier touring car world championship, the Kumho FIA TCR World Tour. WSC Group is backed by a consortium of strategic investors who are committed to driving the next phase of the company's global expansion and public listing. Media Contact: Kefi B.V. Corporate Communications Amsterdam / Hong Kong media@kefi-bv.com Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com
Results Highlights: - Revenue increased by 18.1% year-on-year to US$98.7 million, with all geographical markets recording growth. - Gross profit grew by 21.0% to approximately US$67.7 million, with gross profit margin increasing to 68.5%. - Profit for the period attributable to owners of the Company rose by 9.0% to US$21.6 million; core operating profit grew by 20.1% to US$18.1 million. - The Board declared its first-ever interim dividend of HK8 cents per share. - Direct sales accounted for 60.3% of total revenue, with the network expanding to 15 markets, including newly established direct sales teams in the Netherlands, Belgium, and Luxembourg. - The Hangzhou R&D and manufacturing facility is expected to receive its final acceptance certificate in September 2026 and commence operations by the end of 2027; the Group plans to establish a new manufacturing facility in Indonesia to cater to local demand. - To seize opportunities from the “leave nothing behind” trend, the Group’s proprietary coronary paclitaxel DCB has officially commenced clinical trial in Japan with patient enrolment underway. HONG KONG, August 13, 2026 - (ACN Newswire) - OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”), today announced its interim results for the six months ended June 30, 2026 (the “Period”). Despite macro uncertainties, the Group reported growth across all geographical segments. During the Period, the Group’s revenue increased by 18.1% year-on-year to US$98.7 million, supported by sustained product popularity across all regions. Gross profit reached approximately US$67.7 million, an increase of 21.0% from the corresponding period last year, while the gross profit margin rose by 1.6 percentage points to 68.5%. Profit for the period attributable to owners of the Company amounted to US$21.6 million, representing an increase of 9.0% year-on-year. Core operating profit, defined as profit for the period attributable to owners of the Company excluding share-based compensation expenses, net tax credit from deferred tax assets related to tax losses and finance income – net, amounted to US$18.1 million, up 20.1% year-on-year. Basic earnings per share rose to US2.62 cents (first half of 2025: US2.40 cents). The Group maintained a robust financial position, with cash and bank balances (including long-term bank deposits) of approximately US$224.3 million as at June 30, 2026. The Board remains confident in the Group’s business outlook and, having carefully reviewed its capital requirements and dividend policy, has resolved to declare an interim dividend of HK8 cents per share. This marks the Group’s first interim dividend distribution in its history and demonstrates its commitment to creating value and delivering attractive returns to shareholders. Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “Despite a complex and volatile global macroeconomic environment, OrbusNeich achieved growth in all major geographical markets, demonstrating the effectiveness of our business strategies, the strength of our global commercial platform and the industry’s trust in our brand. Product innovation remains the cornerstone of our development. Through proprietary R&D and strategic collaborations, we continue to enrich our portfolio while refining our global sales footprint and manufacturing capacity to build a more resilient business ecosystem. The Board’s decision to declare our first interim dividend reflects our confidence in the Group’s prospects and our commitment to creating shareholder value. Looking ahead, we will continue to leverage our competitive strengths to provide quality medical solutions to patients worldwide and generate sustained value for all stakeholders.” Healthy Growth Across All Geographical Markets All geographical markets recorded various degrees of growth during the Period. The strong performance of the Group’s proprietary and third-party products, coupled with the direct channel benefiting from the integration of the Taiwan distributor, drove revenue in APAC up 24.5% year-on-year to US$34.0 million. Revenue from the EMEA region grew significantly by 16.7% to US$26.2 million. Limited impacts on the Middle East markets were seen despite the ongoing regional conflict, while European direct sales markets such as Germany, France and Spain delivered robust performance. Meanwhile, the Group’s proactive strategy of participating in volume-based procurement (VBP) programs in the Mainland of China yielded results, with revenue from this market growing 4.8% year-on-year to US$10.1 million. As the Japan and US markets benefited from increased sales of new-generation and high-performance products, revenue from these two markets rose by 6.4% and 5.6%, respectively, reaching US$17.1 million and US$7.9 million. Unleashing Potential of the Robust Global Sales Network OrbusNeich’s sales network covers more than 70 countries and regions worldwide. In the first half of 2026, the Group officially launched local sales teams in Belgium, the Netherlands and Luxembourg, successfully transitioning these markets to the direct sales model. This expansion has brought the total number of direct sales markets to 15, which contributed 60.3% of total revenue for the Period. Leveraging its widely recognized global commercialization capabilities, the Group continues to seek strategic partnerships with medical device manufacturers in order to capitalize on opportunities arising from the international expansion of Chinese healthcare companies and to enrich its product offerings. Since 2024, the Group has partnered with SonoScape to introduce its intravascular ultrasound (IVUS) products into select overseas direct sales markets. Product sales continued to grow during the Period and the market response was positive, fully demonstrating the success of this collaboration. Steady Progress in Innovative R&D, Proactive Positioning for the “Leave Nothing Behind” Trend OrbusNeich regards R&D as a core strategic pillar. As at June 30, 2026, the Group held over 215 granted patents and published patent applications in major jurisdictions worldwide, with more than 55 approved products, including 37 PMDA-approved products, 42 CE-marked products, 21 FDA-cleared or approved products, and 27 NMPA-approved products. During the Period, the Group continued to achieve milestones in product registrations and clinical trials, including: - Obtaining PMDA approvals for Sapphire NC ULTRA and Sapphire ULTRA, NMPA approvals for Scoreflex TRIO and Sapphire NC 24, and FDA approval for Teleport Glide; - Submitting applications for FDA approval of JADE Score and Sapphire 3, CE certification for Scoreflex QUAD, and NMPA approval for Teleport Glide, Sapphire NC Ultra, Sapphire ULTRA and JADE PLUS; In addition, patient enrolment for the clinical trial of its proprietary coronary paclitaxel drug-coated balloon (DCB) commenced in July 2026 in Japan. Completion is expected within 16 months, with the product’s first launch anticipated in Japan in 2030. The Group also plans to initiate its clinical studies in the Mainland of China for NMPA registration and CE mark application in the second half of 2026. Development plans for next-generation standard balloons are also in place to further strengthen its product portfolio. Optimizing Global Production Capability to Build a Foundation for Long-Term Growth As at June 30, 2026, the Group operates production facilities in Shenzhen, the PRC; Hoevalaken, the Netherlands; and Weil am Rhein, Germany, with an aggregate annual production capacity of approximately 2.1 million units of balloons and stents. To meet growing global demand, construction of the Hangzhou R&D and manufacturing facility is progressing steadily, with interior fitting out works, mechanical equipment installation, and external landscaping well underway. The facility is expected to receive the final acceptance certificate in September 2026 and is scheduled to commence operations by the end of 2027. Additionally, to strengthen its key growth engine in Southeast Asia, the Group plans to invest approximately US$2 million to establish a production base with GFA of 1,500 square meters in Indonesia, from which it will supply balloons locally to meet rising demand. Mr. Chien concluded, “Looking ahead, the Group expects to maintain strong revenue growth in the near term, supported by rising sales of eucatech AG and Scoreflex QUAD products, as well as the accelerated commercialization of third-party products, including IVUS products. In the medium to long term, we will continue to expand our PCI therapeutic portfolio, with our proprietary DCB product progressing on schedule toward regulatory approvals and positioned to become a key growth driver. We will also pursue organic team building and selective acquisitions to strengthen our European presence, enhance global competitiveness, and create sustainable value for patients, healthcare professionals and shareholders.” About OrbusNeich Medical Group Holdings Limited OrbusNeich is a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, our Group sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease. With an in-house R&D team boasting over 25 years of product development expertise, our Group has developed world-leading proprietary technologies. For more information, please visit the Group’s official website: https://orbusneich.com/. Media Inquiries Strategic Financial Relations Limited Angelus Lau Tel: (852) 2864 4805 Email: angelus.lau@sprg.com.hk Doris Ho Tel: (852) 2114 4916 Email: doris.ho@sprg.com.hk Bailey Zhou Tel: (852) 2114 2825 Email: bailey.zhou@sprg.com.hk Website: https://www.sprg.com.hk/ OrbusNeich Medical Group Holdings Limited Maggie Lau Tel: (852) 3109 7234 Email: mlau@orbusneich.com Lucille Tsang Tel: (852) 3109 7292 Email: ltsang@orbusneich.com Website: https://orbusneich.com/ Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com
Calgary, Canada, 2026-08-13 — /EPR Network/ — Evan’s Cash For Cars is proud to announce the expansion of its junk car removal in Calgary. This [read full press release...]
(PR-inside.com) News Release Highlights: Battery X Metals appoints electric vehicle and lithium-ion battery entrepreneur William Fan as President to advance its patent-pending lithium-ion battery rebalancing technology development, expand strategic industry relationships, advance corporate development initiatives, including evaluating complementary opportunities within the broader battery ecosystem, and support the Company's capital markets initiatives. Mr. Fan previously led a bid to acquire the intellectual property and operating assets of ElectraMeccanica Vehicles Corp., a Nasdaq-listed electric vehicle manufacturer at the time, and brings experience spanning the electric vehicle, lithium-ion battery, energy storage, corporate development, and capital markets sectors, complemented by ma
News Release Highlights: Battery X Metals appoints electric vehicle and lithium-ion battery entrepreneur William Fan as President to advance its patent-pending lithium-ion battery rebalancing technology development, expand strategic industry relationships, advance corporate development initiatives, including evaluating complementary opportunities within the broader battery ecosystem, and support the Company's capital markets initiatives. Mr. Fan previously led a bid to acquire the intellectual property and operating assets of ElectraMeccanica Vehicles Corp., a Nasdaq-listed electric vehicle manufacturer at the time, and brings experience spanning the electric vehicle, lithium-ion battery, energy storage, corporate development, and capital markets sectors, complemented by manufacturing trai
HANGZHOU, China, Aug. 12, 2026 /PRNewswire/ -- Farizon New Energy Commercial Vehicle Group hosted its 10‑year‑anniversary roll‑off ceremony at its Ma'anshan manufacturing plant, with on‑site employees on hand to witness the landmark 600,000th unit — a Homtruck heavy truck calibrated to...